title: A randomized phase III study of combining erlotinib with bevacizumab and panitumumab versus erlotinib alone as second-line therapy for Chinese patients with non-small-cell lung cancer.
abstract: OBJECTIVE
  In this phase III clinical study, we assessed the clinical outcomes of combining erlotinib with bevacizumab and panitumumab as second-line chemotherapy for patients with non-small-cell lung cancer (NSCLC).
  
  
  METHODS
  Chinese NSCLC patients, who received first-line platinum-based chemotherapy but still experienced disease progression, were assigned to receive second-line treatment of erlotinib plus bevacizumab and panitumumab (arm I), or erlotinib plus placebo (arm II). The primary endpoint was progression-free survival (PFS). The secondary endpoints were overall survival (OS) and response rates.
  
  
  RESULTS
  150 patients were enrolled in arm I, and 147 in arm II. Median PFS of arm I was 4.6 months (95% CI, 2.3-9.4 months), much longer than the median PFS in arm II (1.9 months, 95% CI 0.8-5.2 months) (P=0.003). The median OS of arm I was 10.4 months (95% CI, 7.5-13.1 months), also significantly longer than the median OS in arm II (8.9 months, 95% CI 3.3-10.9 months) (P=0.031). Partial response in arm I was 38%, significantly higher than the partial response rate of 15% in arm II (P=0.014). The occurrence rates of adverse events, including diarrhea, fatigue and rash, were higher in arm I than in arm II.
  
  
  CONCLUSIONS
  Erlotinib plus bevacizumab and panitumumab is an efficient second-line treatment option for patients with NSCLC.
authors.affiliation: Department of Integrative Oncology, Cancer Center and Department of Clinical Pharmacy, Xiaoshan Hospital, Hangzhou, 311202, Zhejiang Province, China.
authors.forename: Ying
authors.initials: Y
authors.lastname: Wang
authors.affiliation: Department of Integrative Oncology, Cancer Center and Department of Clinical Pharmacy, Xiaoshan Hospital, Hangzhou, 311202, Zhejiang Province, China.
authors.forename: Hui
authors.initials: H
authors.lastname: Wang
authors.affiliation: Department of Integrative Oncology, Cancer Center and Department of Clinical Pharmacy, Xiaoshan Hospital, Hangzhou, 311202, Zhejiang Province, China.
authors.forename: Yiling
authors.initials: Y
authors.lastname: Jiang
authors.affiliation: Department of Integrative Oncology, Cancer Center and Department of Clinical Pharmacy, Xiaoshan Hospital, Hangzhou, 311202, Zhejiang Province, China.
authors.forename: Yaping
authors.initials: Y
authors.lastname: Zhang
authors.affiliation: Department of Integrative Oncology, Cancer Center and Department of Clinical Pharmacy, Xiaoshan Hospital, Hangzhou, 311202, Zhejiang Province, China. Electronic address: wjj334@aol.com.
authors.forename: Xiaoyan
authors.initials: X
authors.lastname: Wang
mesh_terms: D000328:Adult; D000368:Aged; D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000627:therapeutic use; D044466:Asian People; D000068258:Bevacizumab / Q000008:administration & dosage / Q000627:therapeutic use*; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy*; D004359:Drug Therapy, Combination; D000069347:Erlotinib Hydrochloride / Q000008:administration & dosage / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D000077544:Panitumumab
chemical_list: D000911:Antibodies, Monoclonal; D000970:Antineoplastic Agents; D000068258:Bevacizumab; D000077544:Panitumumab; D000069347:Erlotinib Hydrochloride
keywords: Bevacizumab; Erlotinib; NSCLC; Panitumumab; Survival